2. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

3. Kaprin A.D., Starinsky V.V., Petrova G.V. The status of cancer care for the population of Russia in 2017. M.: FSBI “MNIII named after P.A. Herzen” Ministry of Health of Russia. 2018 (Каприн А.Д., Старинский В.В.,Петрова Г.В. Состояние онкологической помощи населениюР оссии в 2017 году. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России. 2018).

4. Mouraviev V. et al. Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol. 2009;6:205.

5. Cooperberg M.R. et al. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178:S14.

6. Polascik T.J. et al. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate, 2008;68:1380.

7. Chernyshev I.V., Samsonov Yu.V., Perepechin D.V., Koryakin A.V., Osipov O.V.Quality of life and social adaptation of patients after radical prostatomy and interstitial radiation therapy. Modern methods of treatment of urological diseases. 2013;4:106–108 (Чернышев И.В., Самсонов Ю.В., Перепечин Д.В., Корякин А.В., Осипов О.В. Качество жизни и социальная адаптация пациентов после радикальной простатэктомии и интерстициальной лучевой терапии. Современные методы лечения урологических заболеваний. 2013;4:106–108).

8. Machtens S. et al. Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol. 2006;24:289.

9. Hocht S. et al. Erratum to: Hypofractionated radiotherapy for localized prostate cancer. Strahlenther Onkol. 2016;192: 830.

10. Dearnaley D., Syndikus I., Mossop H., Khoo V., Birtle A., Bloomfield D., Graham J., Kirkbride P., Logue J., Malik Z., Money-Kyrle J., O’Sullivan J.M.,Panades M., Parker C., Patterson H., Scrase C., Staffurth J., Stockdale A.,Tremlett J., Bidmead M., Mayles H., Naismith O., South C., Gao A., Cruickshank C., Hassan S., Pugh J., Griffin C., Hall E.; CHHiP Investigators. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–1060.

11. Talcott J.A., Manola J., Clark J.A. et al. Time course and predictors of symptoms aÀer primary prostate cancertherapy. J Clin Oncol 2003;21(21):3979–3986.

12. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate- cancer survivors. N Engl J Med 2008;358(12):1250–1261.

13. Brassel S.A., Elsamanoudi S.I., Cullen J. et al. Health-related quality of life for men with prostate cancer- an evaluation of outcomes 12-24 months aÀer treatment. Urol Oncol, 2012 May 17.

14. Strouthos I., Tselis N., Chatzikonstantinou G., Butt S, Baltas D., Bon D., Milickovic N., Zamboglou N. High dose rate brachytherapy as monotherapy for localised prostate cancer. Radiother Oncol. 2018;126(2):270–277.

15. Pieters B.R., et al. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol 2009;93:168.

16. Hoskin P.J., et al. Randomised trial of external beam radiotherapy alone or combined with high- dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103:217.

17. Budaus L., et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol. 2012;61:112.

18. Hauswald H., Kamrava M.R., Fallon J.M., Wang P.C., Park S.J., Van T., Borja L., Steinberg M.L., Demanes D.J. High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results. Int J Radiat Oncol Biol Phys. 2016;94(4):667–674. Doi: 10.1016/j.ijrobp.2015.07.2290.

19. Chen C.P., et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013;86:324.

20. Burri R.J., et al. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 2010;77:1338.

21. Moman M.R., et al. Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy. 2010;09:119.

22. Mazzini M., Sehrt D., Pompeo A. Biophysiological considerations in cryoablation: a practical mechanistic molecular review of Braz J Urol 2011.37: 693–696.

23. Govorov A.V., Shaderkin I.A. Prostate Cryoablation. Russian (Говоров А.В.,Шадеркин И.А. Криоаблация предстательной железы). https://www.uroweb.ru/article/db-article-krioablaciya-predstatelnoi-zhelezy

24. Govorov AV, Cryoablation in the treatment of prostate cancer. Diss. Doc Honey. Science. Moscow, 2016 (Говоров А.В., Криоаблация в лечении рака предстательной железы. Дисс. док. мед. наук. Москва, 2016).

25. GovorovA.V., PushkarD.Yu., IvanovV.Yu. Experience with prostate cancer treatment using cryoablation (Говоров А.В., Пушкарь Д.Ю., Иванов В.Ю.Опыт лечения рака предстательной железы при помощи криоаблации). https://www.mpamed.ru/info/publications/lechenie-raka-s-pomoschy-crio/

26. https://uroweb.org/guidelines/

27. Robinson J.W., Donnelly B.J., Saliken J.C., et al. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology 2002;60 (2 Suppl 1):12–18.

28. Robinson J.W., Donnelly B.J., Siever J.E., et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer 2009t;115(20):4695–704.

29. Aus G., Burnett A., Kandy-Hagino I.D. Prostate Cancer: guidelines for the treatment of clinically localized prostate Ca Am Urol Assoc Educ Res 2007-1-254. https: // www. auanet.org/guidelin/prostate-cancer.

30. Oishi M., Gill I.S., Ashrafi A.N., Lin-Brande M., Nassiri N., Shin T., Bove A.,Cacciamani G.E., Ukimura O., Bahn D.K., Abreu A.L.C. Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up. Eur Urol. 2019;75(2):208–214. Doi: 10.1016/j.eururo.2018.09.004.

31. Ismail M., et al. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int. 2007;100:760.

32. Pisters L.L., et al. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180:559.

33. Bahn D.K., Lee F., Baldalament R., et al. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002;60(2 Suppl 1):3–11.

34. Madersbacher S., Marberger M. High-energy shockwaves and extracorporeal high-intensity focused ultrasound. J Endourol 2003;17(8):667–672.

35. Wu F., Wang Z.B., Wang Z.L., et al. Changes in ultrasonic image of tissue damaged by high intensity ultrasound in vivo. J. Acoustic Soc. Am. 1998. 103. С. 2869.

36. Crouzet S.L, Poissonnier L., Murat F.J., Pasticier G., Rouvière O., Mège-Lechevallier F., Chapelon J.Y., Martin X., Gelet A. Outcomes of HIFU for localised prostate cancer using the Ablatherm Integrate Imaging® device. Prog Urol. 2011;21(3):191–97. doi: 10.1016/j.purol.2010.07.005.

37. Blana A., Murat F.J., Walter B. et al. First analysis of long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2008; 53: 1194.

38. Mearini L.L, D’Urso L., Collura D., Nunzi E., Muto G., Porena M. High-intensity focused ultrasound for the treatment of prostate cancer: A prospective trial with long-term follow-up. Scand J Urol. 2015;49(4):267–274. Doi: 10.3109/21681805.2014.988174.

39. Rosenhammer B., Ganzer R., Zeman F., Näger T., Fritsche H.M., Blana A., Burger M., Bründl J. Oncological long-term outcome of whole gland HIFU and open radical prostatectomy: a comparative analysis. World J Urol. 2019 Jan 2. Doi: 10.1007/s00345-018-2613-z.

40. Limani K., Aun E., Holz C., etc. One session of high-intensity focused ultrasound as the primary treatment of whole gland for clinically localized prostate cancer: 10-year result prostate Cancer 2014;2014:186782.

41. Dickinson L., Arya M., Afzal N. mid-Term results after treatment of HIFU of non-metastatic prostate cancer from a multicenter registration cohort. Eur Urol 2016;70:668.

42. El Fegoun A.B., Barret E., Prapotnik D. et al Focal therapy high-intensity focused ultrasound in prostate cancer in the elderly: feasibility study with 10 years observation. Int Braz J Urol 2011,37: 213.

43. Babalola O.T., I. Lee, S.J. Viviano. Prostate ablation using high-intensity focused ultrasound: a review of the literature on the potential role of information in patient preferences. Urol 2016, 19: 79–83.

44. Krupinov G.E. Treatment of patients with prostate cancer with high-intensity focused ultrasound. Diss. Doc. Med. Science. Moscow 2010 (Крупинов Г.Е. Лечение больных раком предстательной железы высокоинтенсивным фокусированным ультразвуком. Дисс. док. мед. наук. М., 2010).

45. Jones, T.A., Chin D. McLeod and others. High-intensity focused ultrasound for prostate cancer radioreceiver: North American clinical trial. J Urol 2018: 199: 133.

46. Murat F.J., Poissonnier L, Rabilloud M., etc. Mid-term results demonstrate high-intensity focused ultrasound (HIFU) as an effective and acceptable pathological treatment option for local radioreceiver prostate cancer Eur Urol 2009; 55: 640.

47. Govorov A.V., Vasiliev A.O., Pushkar D.Yu. Focal cryoablation of the prostate. Experimental and clinical urology. 2013;2. Russian (Говоров А.В., Васильев А.О., Пушкарь Д.Ю. Фокальная криоаблация предстательной железы Экспериментальная и клиническая урология. 2012;2).

48. Tay K.J., Amin M.B., Ghai S., Jimenez R.E., Kench J.G., Klotz L., Montironi R., Muto S., Rastinehad A.R., Turkbey B., Villers A., Polascik T.J. Surveillance after prostate focal therapy. World J Urol. 2018. Doi: 10.1007/s00345-018-2363-y.

49. Valerio M., et al. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol. 2017;71:17.

50. Onik G., Narayan P., Vaughan D., Dineen M., Brunelle R. Focal «nerve-sparing» cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology. 2002;60(1):109–114.

51. Onik G., Vaughan D., Lotenfoe R., Dineen M., Brady J. The «male lumpectomy»: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol. 2008;26(5):500–505. Doi: 10.1016/j.urolonc.2008.03.004.

52. Donelly B.J., Saliken J.C., Ernst D.S., Ali et al. Prospective trial of cryosurgical ablation of the prostate:five year results. Urology 2002;60(4):645–649.

53. Fowler Jr., Barry M.J. Lou-J. Yao. Results Of external radiation therapy for prostate cancer: a study of Medicare recipients in three areas of surveillance, epidemiology, and outcomes. J Clin Oncol. 1996;14:2258–2265.

54. Van Velthoven R., Aun F.K. Marselis etc. Prospective clinical investigation of HIFU with Emblaze clinically localized prostate cancer. Prostate cancer Dis 2016;19:79–83.

55. Sang H.H, Jong B.C., S. and Seo, etc. Seven years of experience with high-intensity focused ultrasound in prostate cancer: advantages and limitations. Prostate 2012;72:1399.

56. Bown S.G. Phototherapy of tumors. World Journal of Surgery. 1983;7 (6):700–789.

57. Amin Z., Lees W.R., Bown S.G. Technical note: interstitial laser photocoagulation for the treatment of prostatic cancer. British Journal of Radiology. 1993;66(791):1044–1047.

58. Colin P., Nevoux P., Marqa M. Focal laser interstitial thermotherapy (LITT) at 980 nm for prostate cancer: treatment feasibility in Dunning R3327-AT2 rat prostate tumor. British Journal of Urology Inernational. 2011;109(3):452–458.

59. Azzouzi A.R., Barret E., Moore C.M., Villers A., Allen C., Scherz A., et al. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int. 201;3:112(6):766–774.

60. Moore C.M., Azzouzi A.R., Barret E., Villers A., Muir G., et al. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localized prostate cancer using WST11-Vascular Targeted Photodynamic (VTP) therapy. BJU Int. 2014. Doi: 10.1111/bju.12816.

61. Wiggermann P., Brünn K., Bäumler W. Irreversible electroporation (IRE): A minimally invasive therapeutic option in prostate cancer. Radiologe. 2017;57(8):637–640.

62. Dong S., Wang H., Zhao Y., Sun Y., Yao C. First Human Trial of High-Frequency Irreversible Electroporation Therapy for Prostate Cancer. Technol Cancer Res Treat. 2018;17:1533033818789692. Doi: 10.1177/1533033818789692.

63. Valerio M., et al. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol. 2017;1:17.

64. Murray K.S., Ehdaie B., Musser J., Mashni J., Srimathveeravalli G., Durack J.C., Solomon S.B., Coleman J.A. Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer. J Urol. 2016;196(3):883–890. Doi: 10.1016/j.juro.2016.02.2986.

65. Scheltema M.J., Chang J.I., Böhm M., van den Bos W., Blazevski A., Gielchinsky I., Kalsbeek A.M.F., van Leeuwen P.J., Nguyen T.V., de Reijke T.M., Siriwardana A.R., Thompson J.E., de la Rosette J.J., Stricker P.D.Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World J Urol. 2018;36(9):1383–1389. Doi: 10.1007/s00345-018-2281-z.